26766-35-8

Upstream product

• 4595-59-9 5-bromopyrimidine 
• 90-98-2 4,4'-Dichlorobenzophenone 

Downstream Products

• 101989-14-4 α,α-bis(4-chlorophenyl)-1H-pyrazole-4-methanol 
• 112959-07-6 8-chloro-5-(4-chlorophenyl)-5 H-indeno[1,2-d]pyrimidine 
• 108394-98-5 5-[1,1,2-Tris-(4-chloro-phenyl)-ethyl]-pyrimidine 
• 108394-97-4 5-[1,1-Bis-(4-chloro-phenyl)-2-phenyl-ethyl]-pyrimidine 
• 108394-96-3 5-[1,1-Bis-(4-chloro-phenyl)-propyl]-pyrimidine 
• 93765-56-1 5-<1,1-bis(4-chlorophenyl)ethyl>-pyrimidine 
• 102993-90-8 5-[Bis-(4-chloro-phenyl)-imidazol-1-yl-methyl]-pyrimidine 
• 108394-94-1 α,α-bis(4-chlorophenyl)-5-pyrimidinemethanol 1-oxide 
• 108394-99-6 5--pyrimidine 
• 93765-55-0 5--pyrimidine 
• 26766-37-0 α,α-bis(4-chlorophenyl)-5-methylpyrimidine 
• 108395-11-5 5--1,4,5,6-tetrahydropyrimidine 
• 108395-10-4 5--1,6-dihydropyrimidine 
• 123124-64-1 1-[bis(4-chlorophenyl)pyrazol-4-ylmethyl]-imidazole 

Relevant academic research and scientific papers

Analogues of fenarimol are potent inhibitors of trypanosoma cruzi and are efficacious in a murine model of chagas disease

We report the discovery of nontoxic fungicide fenarimol (1) as an inhibitor of Trypanosoma cruzi (T. cruzi), the causative agent of Chagas disease, and the results of structure-activity investigations leading to potent analogues with low nM IC50s in a T. cruzi whole cell in vitro assay. Lead compounds suppressed blood parasitemia to virtually undetectable levels after once daily oral dosing in mouse models of T. cruzi infection. Compounds are chemically tractable, allowing rapid optimization of target biological activity and drug characteristics. Chemical and biological studies undertaken in the development of the fenarimol series toward the goal of delivering a new drug candidate for Chagas disease are reported.

Biological evaluation of 5-substituted pyrimidine derivatives as inhibitors of brassinosteroid biosynthesis

A series of 5-substituted pyrimidine derivatives was synthesized, and their ability to inhibit brassinosteroid biosynthesis was tested. The biological activity of these compounds was evaluated by the cress stem elongation method. Among the synthesized com

Estrogen Synthetase Inhibitors. 2. Comparison of the in Vitro Aromatase Inhibitory Activity for a Variety of Nitrogen Heterocycles Substituted with Diarylmethane or Diarylmethanol Groups

The preparation and in vitro aromatase inhibitory activity of a wide variety of heterocyclic (4,4'-dichlorodiphenyl)methanes and -methanols are described.The choice of the two diaryl-bearing moieties as a vehicle for the evaluation of the heterocycles was made by the comparison of series of imidazole and pyridine-derived compunds with similar pyrimidine compounds reported previously.A structural model for the most active compounds is also presented.The activity of a related series of compounds which contain two heterocyclic moieties was found to be consistent with the model.Many of the compounds evaluated, including representatives of the pyridine, imidazole, pyrimidine, pyrazole, triazole, thiazole, and isothiazole classes, exhibit EC50 potencies for aromatase inhibition at low nanomolar levels.These compunds are at least as potent as other nonsteroidal aromatase inhibitors reported previously.

Aromatase Inhibition by 5-Substituted Pyrimidines and Dihydropirimidines

The inhibition of estrogen biosynthesis has been suggested to be an effective treatment of hormone-dependent diseases, particularly breast cancer.Several series of 5-substituted pyrimidine derivatives have been synthesized and tested for their ability to inhibit the enzyme aromatase (estrogen synthetase).Compounds were evaluated in an in vitro assay that measured the inhibition of rat ovarian microsomal aromatase activity.Greatest inhibitory activity was achieved in the cases of diarylpyrimidinemethanols and diarylpyrimidinyl methanes which were substituted in the 4- and 4'-positions with electron-withdrawing substituents, particularly Cl.